
GW Pharmaceuticals plc Long-Term Debt 2011-2025 | GWPH
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt GW Pharmaceuticals plc
2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|
- | 14.7 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
Maximum | Minimum | Average |
---|---|---|
14.7 M | 14.7 M | 14.7 M |
Long-Term Debt of other stocks in the Drug manufacturers industry
Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
---|---|---|---|---|---|---|
![]() |
Amryt Pharma plc
AMYT
|
188 M | $ 14.7 | - | $ 621 M | ![]() |
![]() |
Aerie Pharmaceuticals
AERI
|
21.8 M | $ 15.25 | - | $ 754 M | ![]() |
![]() |
PetIQ
PETQ
|
438 M | $ 13.6 | 1.64 % | $ 400 M | ![]() |
![]() |
Agile Therapeutics
AGRX
|
1.52 M | $ 0.6 | 10.11 % | $ 58.2 M | ![]() |
![]() |
Teligent, Inc.
TLGT
|
137 M | $ 0.173 | -13.85 % | $ 16.1 M | ![]() |
![]() |
Recro Pharma
REPH
|
339 K | $ 1.4 | -4.76 % | $ 65.3 M | ![]() |
![]() |
Athenex
ATNX
|
93 K | $ 0.2 | -23.39 % | $ 1.76 M | ![]() |
![]() |
Ironwood Pharmaceuticals
IRWD
|
199 M | $ 1.58 | 3.95 % | $ 251 M | ![]() |
![]() |
PLx Pharma
PLXP
|
622 K | $ 0.09 | -27.8 % | $ 2.56 M | ![]() |
![]() |
Shineco, Inc.
TYHT
|
402 K | $ 11.09 | -3.90 % | $ 97.2 M | ![]() |
![]() |
Lannett Company
LCI
|
615 M | $ 0.66 | 1.15 % | $ 7.11 M | ![]() |
![]() |
Calliditas Therapeutics AB (publ)
CALT
|
24.1 M | $ 40.0 | -0.1 % | $ 2.03 B | ![]() |
![]() |
Adamas Pharmaceuticals, Inc.
ADMS
|
126 M | $ 8.22 | - | $ 376 M | ![]() |
![]() |
Organogenesis Holdings
ORGO
|
718 K | $ 4.13 | -0.24 % | $ 544 M | ![]() |
![]() |
Flexion Therapeutics, Inc.
FLXN
|
207 M | $ 9.12 | - | $ 459 M | ![]() |
![]() |
Kindred Biosciences, Inc.
KIN
|
18.5 M | $ 9.25 | 0.11 % | $ 419 M | ![]() |
![]() |
Neos Therapeutics, Inc.
NEOS
|
29.1 M | $ 1.15 | -2.54 % | $ 57.2 M | ![]() |
![]() |
Endo International plc
ENDP
|
8.15 B | $ 0.29 | - | $ 28.9 M | ![]() |
![]() |
Tricida
TCDA
|
11.3 M | $ 0.11 | - | $ 3.25 M | ![]() |
![]() |
PPD, Inc.
PPD
|
4.23 B | $ 47.25 | 0.13 % | $ 16.6 B | ![]() |
![]() |
Bausch Health Companies
BHC
|
21.9 B | $ 6.34 | -0.78 % | $ 2.31 B | ![]() |
![]() |
HEXO Corp.
HEXO
|
29 M | $ 0.71 | 2.45 % | $ 38.1 M | - |
![]() |
Veru
VERU
|
2.92 M | $ 4.41 | 1.38 % | $ 595 M | ![]() |
![]() |
Neptune Wellness Solutions
NEPT
|
17.1 M | $ 0.2 | -45.3 % | $ 917 K | ![]() |
![]() |
Taro Pharmaceutical Industries Ltd.
TARO
|
4.98 M | $ 42.97 | - | $ 1.62 B | ![]() |
![]() |
Viatris
VTRS
|
18 B | $ 9.97 | -1.68 % | $ 12.1 B | ![]() |
![]() |
Horizon Therapeutics Public Limited Company
HZNP
|
2.55 B | $ 116.3 | - | $ 26.6 B | ![]() |
![]() |
cbdMD
YCBD
|
2.4 M | $ 1.43 | -3.38 % | $ 6.17 M | ![]() |
![]() |
FSD Pharma
HUGE
|
147 K | $ 5.84 | 5743.5 % | $ 69.7 M | ![]() |
![]() |
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | $ 0.78 | 0.86 % | $ 117 M | ![]() |
![]() |
Zynerba Pharmaceuticals
ZYNE
|
120 K | $ 1.3 | - | $ 55.5 M | ![]() |
![]() |
Guardion Health Sciences
GHSI
|
3.81 K | $ 3.25 | -0.31 % | $ 3.64 M | ![]() |
![]() |
Alimera Sciences
ALIM
|
256 K | $ 5.54 | - | $ 142 M | ![]() |
![]() |
Qilian International Holding Group Limited
QLI
|
106 K | $ 5.41 | -6.08 % | $ 184 M | ![]() |
![]() |
Amneal Pharmaceuticals
AMRX
|
2.16 B | $ 5.91 | 2.6 % | $ 892 M | - |
![]() |
Avadel Pharmaceuticals plc
AVDL
|
1.12 M | $ 14.21 | -1.8 % | $ 1.35 B | ![]() |
![]() |
Johnson & Johnson
JNJ
|
30.7 B | $ 189.69 | 0.42 % | $ 457 B | ![]() |
![]() |
Cumberland Pharmaceuticals
CPIX
|
4.94 M | $ 3.67 | 3.2 % | $ 51.6 M | ![]() |
![]() |
Aurora Cannabis
ACB
|
295 M | $ 6.1 | -1.13 % | $ 86.3 M | - |
![]() |
Eagle Pharmaceuticals
EGRX
|
56.2 M | $ 2.14 | -39.89 % | $ 27.7 M | ![]() |
![]() |
OrganiGram Holdings
OGI
|
104 M | $ 1.94 | -1.02 % | $ 402 M | ![]() |
![]() |
Emergent BioSolutions
EBS
|
446 M | $ 9.89 | -0.3 % | $ 506 M | ![]() |
![]() |
GlaxoSmithKline plc
GSK
|
22.5 B | $ 43.35 | -0.34 % | $ 173 B | ![]() |
![]() |
Radius Health
RDUS
|
315 K | $ 30.0 | - | $ 1.42 B | ![]() |
![]() |
Solid Biosciences
SLDB
|
1.23 M | $ 6.31 | 14.31 % | $ 258 M | ![]() |
![]() |
Catalent
CTLT
|
4.86 B | $ 63.48 | - | $ 11.5 B | ![]() |
![]() |
Pacira BioSciences
PCRX
|
585 M | $ 23.41 | -0.89 % | $ 1.08 B | ![]() |
![]() |
Biogen
BIIB
|
6.3 B | $ 150.97 | -0.81 % | $ 22 B | ![]() |